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Neuregulin-1 (NRG1) plays a crucial role in axoglial signaling during the development of the peripheral nervous system, but its impor-
tance in adulthoodafterperipheral nerve injury remainsunclear.Weused single-neuron labelingwith inducibleCre-mediatedknock-out
animals, which enabled visualization of a subset of adult myelinated sensory and motoneurons neurons in which Nrg1 was inducibly
mutated by tamoxifen treatment. In uninjured mice, NRG1-deficient axons and the associated myelin sheath were normal, and the
neuromuscular junction demonstrated normal apposition of presynaptic and postsynaptic components. After sciatic nerve crush, NRG1
ablation resulted in severe defects in remyelination: axons were either hypomyelinated or had no myelin sheath. NRG1-deficient axons
were also found to regenerate at a slower rate. After nerve injury, the neuromuscular junction was reinnervated, but excess terminal
sproutingwasobserved. JuxtacrineNeuregulin-1 signaling is thereforedispensable formaintenanceof themyelin sheath inadult animals
but has a key role in reparative processes after nerve injury.
Introduction
Neuregulin-1 (NRG1) has a key role in the development of the
peripheral nervous system. Alternative splicing and differential
promoter usage gives rise to at least 15 different NRG1 isoforms
that demonstrate different spatiotemporal patterns of expression
(Meyer et al., 1997; Falls, 2003; Mei and Xiong, 2008). All iso-
forms possess an epidermal growth factor (EGF)-like signaling
domain, which is essential for mediating biological activity, and
can be classified into subgroups according to the structure of
their N termini. Isoforms containing Ig-like domain (types I, II,
and IV) can be either directly secreted or released as soluble pro-
teins from the cell surface after proteolytic cleavage. Isoforms
possessing a cysteine-rich domain (type III isoforms) have two
transmembrane domains, require proteolytic cleavage by BACE1
(-site APP-cleaving enzyme 1) for full activity, and signal in a
juxtacrine manner (Hu et al., 2006; Willem et al., 2006).
During development, axonally derived NRG1 signals via
ErbB2 and ErbB3 receptor heteromers expressed on Schwann
cells and regulates multiple aspects of Schwann cell differentia-
tion, including the survival of Schwann cell precursors, Schwann
cell proliferation, motility, axon ensheathment, and myelination
(Meyer and Birchmeier, 1995; Riethmacher et al., 1997;Morris et
al., 1999; Woldeyesus et al., 1999; Garratt et al., 2000; Chen et al.,
2003; Michailov et al., 2004; Taveggia et al., 2005; Fricker et al.,
2009). Early in vitro studies suggested that NRG1may also have a
role in acetylcholine receptor clustering during development of
the neuromuscular junction (NMJ) (Falls et al., 1993). More re-
cent genetic approaches have however indicated that NRG1–
ErbB signaling is dispensable for postsynaptic differentiation at
the NMJ (Escher et al., 2005; Jaworski and Burden, 2006). NRG1
has also been shown to modulate the behavior of terminal
Schwann cells at the NMJ because it increases survival of these
cells after postnatal denervation (Trachtenberg and Thompson,
1996) and promotes process extension (Hayworth et al., 2006).
Because of the key developmental role of NRG1 in Schwann
cell development, it has been challenging to study the function of
this molecule in adulthood in relation to both maintenance of
myelin and the response to nerve injury. The peripheral nervous
system shows significant ability for repair after either traumatic
or immune-mediated injury (Chen et al., 2007). The coordinated
signaling between regenerating axons and Schwann cells is likely
to be critical for both axon remyelination and regeneration; given
its developmental functions, NRG1 is an attractive target for ful-
filling such a role. To investigate the role of axon-derived NRG1
signaling, we have used “SLICK” (single-neuron labeling with
inducible Cre-mediated knock-out) mice (Young et al., 2008) in
which the enzyme Cre recombinase is inducibly activated, result-
ing in NRG1 ablation in a subset of myelinated motor and sen-
sory axons that also express yellow fluorescent protein (YFP).We
demonstrate that juxtacrine NRG1 signaling is not required for
maintenance of the myelin sheath and NMJ nor for axon integ-
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rity, but it is essential for multiple aspects
of the reparative response after nerve in-
jury, including remyelination, axon re-




All work performed conformed to United King-
dom Home Office legislation (Scientific Proce-
dures Act 1986). SLICK-A Cre; NRG-1fl/fl were
bred by crossing SLICK-A Cre mice (JAX mice
007606; The Jackson Laboratory) withNRG-1fl/fl
mice; both colonies were on a C57BL/6 back-
ground. The generation and genotyping of mu-
tantmicewith floxed alleles ofNrg1 (Nrg1f/f) and
SLICK-ACremice has been described previously
(Yang et al., 2001; Brinkmann et al., 2008; Young
et al., 2008; Fricker et al., 2009). Genotyping of
SLICK-A Cre; NRG-1fl/fl mice was performed by
using PCR of genomic DNA to detect the pres-
ence of the loxP sites. The primers used were as
follows: 5-TTTGGTGGACTGGGTTTCTC-3
and 5-CTGACTGGCCTTTCTTCCAG-3
(performed as follows; heating at 94°C for 2min,
34 cycles of 94°C for 30 s, 60°C for 30 s, and 72°C
for50 s, followedbya final extensionat 72°C for8
min). To detect the SLICK-A Cre construct, ear
puncheswereexamined forYFPfluorescenceun-
der a fluorescent microscope.
In SLICK-ACremice, a tamoxifen-inducible
form of Cre recombinase is simultaneously expressed with YFP in the
same cells. Expression is driven by two copies of the Thy1 promoter and
is seen in a small population of motor axons and large DRG cells. YFP
expression is constitutive, whereas Cre activity is drug inducible. Ten-
week-old SLICK-A Cre; NRG-1fl/fl mice were dosed by oral gavage with
0.25 mg/g body weight with tamoxifen (Sigma T5648) in corn oil, pre-
pared as described previously (Young et al., 2008) or with corn-oil-alone
vehicle for 5 consecutive days. After dosing, animals were left for 4 weeks
before surgery. In each experiment, SLICK-A Cre; NRG-1fl/fl tamoxifen-
treated animals were compared with SLICK-A Cre; NRG-1fl/fl vehicle-
treated animals. As an additional control, comparison was also made
with SLICK-A Cre; NRG-1/ tamoxifen-treated controls. We included
equal numbers of animals of each gender in experimental groups when-
ever possible.
Surgery
Onemonth after tamoxifen/vehicle treatment, the right sciatic nerve was
exposed and crushed two times, in twodifferent directions 30 s each time,
with fine forceps. The lesion site was kept a constant 43 mm from the tip
of the third digit, by laying a measured thread over the anatomical tra-
jectory of the sciatic nerve. The crush site was labeled with lamp black.
The wound was closed with 5-0 sutures and disinfected. A schematic
diagram of the sciatic nerve crushmodel is shown in Figure 1. The sciatic
and tibial nerves and the gastrocnemius muscle were harvested at 10 d,
14 d, and 2 months after crush.
In situ hybridization combined with fluorescence histochemistry
Ablation of NRG1 at the mRNA level was demonstrated using in situ
hybridization (ISH) as described previously (Fricker et al., 2009).
After prehybridization treatments (acetylation, delipidation, dehy-
dration), sections were incubated overnight at 37°C with radioactively
([ 35S]dATP; PerkinElmer Life and Analytical Sciences) end-labeled (ter-
minal deoxynucleotidyl transferase; Promega) probe in hybridization
buffer. The probe sequence was CTGGTGATCGTTGCCAAAACTACG-
TAATGGCCAGC (Sigma-Aldrich), directed against the EGF domain
of mouse NRG1 mRNA (NM_178591), and its specificity has been
shown previously. Solutions and materials used during tissue prepara-
tion and prehybridization steps were RNase free or DEPC treated. The
next day, slideswerewashed in SSC solutionswith increasing stringencies
(final wash, 0.2 SSC at 50°C), dehydrated, air dried, dipped in LM1
autoradiographic emulsion (GE Healthcare), and exposed for 3 weeks
before development. Slides weremounted with Vectashield (Vector Lab-
oratories), and signal was visualized on a Carl Zeiss microscope fitted
with an epifluorescence polarized light block. For quantification of ISH
signal in motoneurons, YFP-positive cells exhibiting grain density twice
background levels were counted as exhibiting a positive hybridization
signal. All analyses were performed with the operator blinded to group.
Histology
Immunofluorescence microscopy. Animals were deeply anesthetized with
pentobarbitone and transcardially perfused with 5 ml of saline, followed
by 25 ml of paraformaldehyde (4% in 0.1 M phosphate buffer). L4 DRGs
and gastrocnemius muscle were postfixed in paraformaldehyde (4% in
0.1 M phosphate buffer) for 2 h and then transferred to 20% sucrose
overnight (4°C). Tissue was then mounted in OCT embedding com-
pound on dry ice and stored at80°C. Transverse sections of the DRGs
were cut at 10 m on a cryostat onto SuperFrost Ultra Plus slides. Lon-
gitudinal sections of gastrocnemius were cut on a freezing microtome at
100 m into a 24 well plate and stored in PBS containing 0.1% sodium
azide. Whole tibial nerves were mounted on SuperFrost Ultra Plus slides
in Vectashield mounting medium (Vector Laboratories).
Antibodies. DRG cell profiles were visualized by staining for either
anti--galactosidase (5 Prime33 Prime), IB4 isolectin B4 biotin conju-
gate (10 g/ml; L2140; Sigma-Aldrich), polyclonal sheep calcitonin
gene-related peptide (CGRP) (1:800; CA1137; Biomol), or monoclonal
mouse anti-neurofilament 200 clone N52 (1:500; N0142; Sigma). Sec-
ondary antibodies used were as follows: ExtrAvidin–FITC (1:500; E2761;
Sigma), anti-sheep cyanine 3 (1:400; 713-166-147; Stratech), and donkey
anti-mouse FITC (1:200; 715-095-150; Stratech). For analysis, YFP signal
was enhanced using either rabbit anti-green fluorescent protein (GFP)
(1:1000; A11122; Invitrogen) or chicken anti-GFP (1:1000; 13970-100;
Abcam) and the secondary antibodies Alexa Fluor 488 goat anti-rabbit
(1:1000; A11070; Invitrogen) and Alexa Fluor 488 goat anti-chicken (1:
1000; A11039; Invitrogen). Neuromuscular junctions were visualized using
-bungarotoxin Alexa Fluor 647 conjugate (1:1000; B35450; Invitrogen) or
-bungarotoxin tetramethylrhodamine conjugate (1:1000; T1175; Invitro-
Figure 1. A schematic representation of the sciatic nerve crush model used to assess axon remyelination and regeneration.
Tamoxifen (Tamox.) or vehicle (Veh.)was administered to animals of 10weeks of age for 5 d. At 4weeks later, the sciatic nervewas
crushed at themidthigh level. At 10 d, 14 d, or 8 weeks after sciatic nerve crush, this nerve was harvested at a point 2mmdistal to
the crush site and processed for immunoelectron microscopy. A whole-mount preparation of the tibial nerve was developed to
visualize regenerating YFP-positive axons. The gastrocnemiusmuscle (which is innervated by the tibial nerve)was used for studies
of neuromuscular junction reinnervation.
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gen).Terminal Schwanncellswere visualizedwithS100 stainingusing rabbit
S100 polyclonal antibody (1:400; Z0311; Dako) and secondary Alexa Fluor
546 goat anti-rabbit (1:1000; A11035; Invitrogen). Axonal myelin was visu-
alized using ratmonoclonal tomyelin basic protein (1:200; 7349-2; Abcam)
and secondary Alexa Fluor 546 goat anti-rat (1:1000; A11051; Invitrogen).
Incubation of primary antibodies was overnight and was preceded by incu-
bation with normal donkey serum (S30, 1:10, 30 min; Millipore Bioscience
ResearchReagents).All reagentswerediluted inPBScontaining0.2%Triton
X-100 and 0.1% sodium azide.
Immunofluorescence was visualized under a Carl Zeiss Imager.Z1mi-
croscope or a confocal Carl Zeiss LSM 700 laser scanning microscope.
Photographs were taken using the Axio Cam and AxioVision LE release
4.2 or the LSM Image Browser software for image analysis. Three intact
representative muscle sections were selected from the central third of the
gastrocnemius muscle and analyzed. Counts were taken of total and YFP
axon innervated neuromuscular junctions live on a Carl Zeiss Imager.Z1
microscope, and the experimenter was blinded to the animal group.
Terminal neuromuscular junction sprouts were analyzed from confocal
photomicrographs, 50 images were taken from one section per animal,
and the sprouts were measured using NIH Image J software. The opera-
tor was also blinded to each group for this analysis.
Immunoelectron microscopy
A preembedding immunoelectronmicroscopymethod was applied. An-
imals were deeply anesthetized with pentobarbitone and transcardially
perfused with 5 ml of saline, followed by 25 ml of 4% paraformaldehyde
in 0.1 M phosphate buffer. The sciatic nervewas
dissected and pinned straight on a gelatin-
coated dish. Nerves were postfixed in 4% para-
formaldehyde, 2% glutaraldehyde, and 0.1 M
phosphate buffer at 4°C overnight before being
embedded in 10% gelatin (48724; Sigma); once
the gelatin had set, blocks containing each
nerve were cut and stored in 4%paraformalde-
hyde at 4°C overnight, after which the parafor-
maldehyde was replaced with PBS/0.1% azide.
Transverse sections of sciatic nerves were cut
using a vibratome (LeicaVT1000 S) at 100m.
Sections were stored in PBS/0.1% azide at 4°C.
Sections from 2 mm distal to the crush site
were taken for immunoelectron microscopy.
For YFP staining, gelatin sections of sciatic
nerve were washed in PBS/0.1% bovine serum
albumin (BSA) (A9576; Sigma), incubated for
30 min with 10 mg/ml NaBH4, and then
washed again in PBS/0.1% BSA before incuba-
tion for 20 min with 0.3% H2O2 in PBS. Sec-
tions were then blocked with normal donkey
serum (S30, 1:10, 30 min; Millipore Bioscience
Research Reagents) before incubating over-
night with rabbit anti-GFP in PBS (1:1000;
A11122; Invitrogen). Sections were washed
and then incubated with anti-rabbit biotin in
PBS (1:400, 3 h; BA1000; Vector Laboratories),
and sections were washed before incubation
for 30 min with Vectastain ABC kit (PK-6100;
Vector Laboratories). Sections were washed,
and DAB staining was performed according to
the instructions of themanufacturer with a de-
velopment time of 10 min (DAB Peroxidase
Substrate kit, SK-4100; Vector Laboratories).
Sections were stored in 0.1 M phosphate buffer
at 4°C.
Stained sections were osmicated, dehy-
drated, and embedded in epoxy resin (TAAB
EmbeddingMaterials). Sections of 1m thick-
ness were cut on amicrotome and stained with
toluidine blue before being examined on a light
microscope. Ultrathin sections were cut on an
ultramicrotome and stained with lead uranyl
acetate by the Centre forUltrastructural Imaging, Kings College London.
Sections were mounted on unsupported 100 mesh grids, and sections
were visualized on a Hitachi H7600 transmission electron microscope.
For analysis, photographs of positively stained axons only from each
animal were taken at a magnification of 15,000. All positively stained
axons in the field of view on one mesh grid were photographed and
analyzed, and at least 125 axons were analyzed per experimental group.
Total counts ofmyelinated axonswere performedusing a semithin cross-
section of the whole sciatic nerve at the same level. G-ratios of positively
stained axons were measured per animal using AxioVision LE release 4.2
software.
Statistical analysis
Differences between SLICK-A Cre; NRG-1fl/fl tamoxifen-treated animals
and vehicle-treated controls were determined using the Student’s t test
for comparison of two groups, or one-way ANOVA or two-way ANOVA
using the Tukey’s post hoc test for more than two groups. Results are
reported as mean values SEM. Cumulative frequency of axonal sprout
length were compared statistically using the Kolmogorov–Smirnov test.
Results
Juxtacrine NRG1 signaling is not required for maintenance of
the myelin sheath in adult animals
SLICK-A mice coexpress a tamoxifen-inducible form of Cre re-
combinase and YFP in a subpopulation of motor and sensory
Figure 2. NRG1 ablation is specific to YFP-expressing motoneurons and large DRG cells after tamoxifen treatment. A, In situ
hybridization images using a probe directed against theEGF domain of NRG1 in L4 DRG. B, In situ hybridization images of the
ventral horn of the spinal cord at the level of the lumbar enlargement. Images are of tamoxifen-dosed and vehicle-dosed SLICK-A
Cre; NRG-1fl/fl animals (conditional NRG1 mutant). A population of motoneurons within the ventral horn of the spinal cord and a
small population of DRG cells express YFP (arrows). In tamoxifen-dosed animals, NRG1 expression is absent in these cells (whereas
in YFP-negative cells, expression of NRG1 is maintained). Vh, Vehicle; Tx, tamoxifen. Scale bars, 50m.
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neurons (Young et al., 2008). In the
SLICK-A line, the proportion of mo-
toneurons that express YFP depends on
the spinal level and muscle examined
(Young et al., 2008). At the level of the
lumbar spinal cord, 33.14 2.00% (n
4) of motoneurons (identified by cho-
line acetyltransferase immunostaining)
expressed YFP (supplemental Fig. 1,
available at www.jneurosci.org as sup-
plemental material). In the SLICK-A
mouse, a small percentage (1.7 0.3%)
of DRG cell profiles were also YFP pos-
itive, and all of these DRG cells were
also immunostained for phosphorylated
neurofilament heavy chain (a marker for
DRG cells with large-diameter myelinated
axons) (supplemental Fig. 2, available at
www.jneurosci.org as supplemental mate-
rial) but did not express CGRP or bind IB4
(markers of small-diameter DRG cells with
unmyelinated axons; data not shown).
SLICK-A Cre; ROSA 26 reporter mice
demonstrated clear induction of Cre ac-
tivity (assessed by -galactosidase expres-
sion) in YFP-expressing motoneurons
and DRG cells after tamoxifen but not ve-
hicle administration in the adult (supple-
mental Fig. 2, available at www.jneurosci.
org as supplemental material). SLICK-A
Cre mice were crossed with mice homozy-
gous for theconditionalNrg1allele (Nrg1f/f),
which have loxP sites flanking the se-
quences encoding the essential EGF do-
main (Meyer and Birchmeier, 1995; Yang
et al., 2001; Li et al., 2002). In SLICK-A
Cre; NRG-1fl/fl animals, we used in situ hy-
bridization and a probe directed against the isoform of the EGF
domain to confirm the absence of EGF-domain mRNA se-
quences in YFP-labeled sensory andmotoneurons after adminis-
tration of tamoxifen but not vehicle (Fig. 2). After blinded
analysis of control animals, 94% (49 of 52) of YFP-positive mo-
toneurons expressed EGF domain mRNA, but this was detect-
able in only 9% (9 of 98) of YFP-positive motoneurons in
SLICK-A Cre; NRG-1fl/fl animals after tamoxifen administration.
To determine whether juxtacrine NRG1 signaling was re-
quired for maintenance of the myelin sheath in the naive state,
immunoelectron microscopy was used to identify YFP-positive
axonswithin the sciatic nerve of SLICK-ACre; NRG-1fl/fl animals.
Twelve weeks after tamoxifen or vehicle administration, myelin-
ated fiber morphology was normal (Fig. 3), and there were no
significant differences in G-ratio (0.63  0.01 vs 0.62  0.007,
mean  SE, tamoxifen vs vehicle treatment) or axon diameter
(4.7 0.3 vs 4.3 0.34m, tamoxifen vs vehicle). There was no
difference in the number of YFP axons in the sciatic nerve of
vehicle- or tamoxifen-treated SLICK-A Cre; NRG-1fl/fl mice
(136 22 vs 149 14,mean SE, tamoxifen vs vehicle). Even at
22 weeks after treatment with tamoxifen, myelinated fiber mor-
phology remained normal (Fig. 3), and there were no significant
differences in G-ratio (0.63  0.02 vs 0.6  0.002, tamoxifen vs
vehicle) or axon diameter (5.0 0.04 vs 4.9 0.4m, tamoxifen
vs vehicle).
NRG1 is essential for remyelination after peripheral nerve
injury in adult animals
To investigate a potential function of NRG1 in axon remyelina-
tion and regeneration,we analyzed conditionalmutantmice after
peripheral nerve injury (Fig. 1). At 8 weeks after sciatic nerve
crush, control animals (either vehicle-treated SLICK-A Cre;
NRG-1fl/fl or tamoxifen-treated SLICK-A Cre; NRG-1/)
showed highly effective remyelination (Fig. 4A) (supplemental
Fig. 3, available at www.jneurosci.org as supplemental material).
In contrast, YFP-positive axons of conditional NRG1 mutant
(tamoxifen-treated SLICK-A Cre; NRG-1fl/fl) mice demonstrated
markedly deficient remyelination: a significant proportion of
YFP axons (38.6 3.3%) were ensheathed by Schwann cells but
had failed to elaborate a myelin sheath (including axons of up to
5 m in diameter) (Fig. 4C,E). In tamoxifen-treated SLICK-A
Cre; NRG-1fl/fl animals, the axons that had been remyelinated
displayed a significantly thinner myelin sheath, with an average
G-ratio of 0.84  0.02 (vs 0.72  0.007 and 0.68  0.007 for
vehicle-treated SLICK-A Cre; NRG-1fl/fl and tamoxifen-treated
SLICK-ACre; NRG-1/, respectively; p 0.005) (Fig. 4B,D). In
contrast to the marked changes in G-ratio, the axon diameter of
regenerated YFP-positive axons was unaffected (3.78 0.11 and
3.63  0.18 m vehicle- and tamoxifen-treated SLICK-A Cre;
NRG-1fl/fl, respectively; n 4).
Additional evidence of deficits in remyelination was apparent
when NRG1-deficient YFP-labeled motor axons were visualized
Figure3. JuxtacrineNRG1 signaling is dispensable formaintenance of themyelin sheath in uninjured adult animals. In SLICK-A
animals, YFP-expressing axons can be identified by preembedding immunoelectronmicroscopy by the presence of a dark reaction
product (asterisks). A–D, There is no change in the morphology of YFP-positive axons within the sciatic nerve at 12 (B) or 22 (C)
weeks after administration of tamoxifen to SLICK-A Cre; NRG-1fl/fl mice compared with control animals (12 weeks after vehicle
treatment; A). D, G-ratio frequency distribution in nerves of conditional NRG1 mutant and control mice; n 3–5 per group. Vh.,
Vehicle; Tx., tamoxifen. Scale bars, 2m.
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within the gastrocnemius muscle. Immunohistological analysis
of tamoxifen-treated SLICK-A Cre; NRG-1fl/fl animals 8 weeks
after crush revealed YFP-positive axons along whichmyelin basic
protein (MBP) was absent over long segments, equivalent to the
length of multiple internodes (Fig. 5).
NRG1 is required for effective
regeneration after peripheral nerve
injury in adult animals
To assess long-range axon regeneration,
YFP-labeled axons were visualized in
whole-mount preparations of the tibial
nerve at 10 d, 14 d, or 8 weeks after sciatic
nerve crush (Fig. 6). Compared with ax-
ons in uninjured tibial nerve, the regener-
ating axons were thinner and growth
cones could be identified (supplemental
Fig. 4, available at www.jneurosci.org as
supplemental material). At 10 d after sci-
atic nerve crush, YFP-positive axons from
tamoxifen-treated SLICK-A Cre; NRG-
1fl/fl animals demonstrated a significant
reduction in regeneration distance from
the crush site compared with control (ei-
ther vehicle-treated SLICK-A Cre; NRG-
1fl/fl or tamoxifen-treated SLICK-A Cre;
NRG-1/ animals; p  0.05, two-way
ANOVA) (Fig. 6) (supplemental Fig. 4,
available at www.jneurosci.org as supplementalmaterial). At 14 d
after crush, although the YFP-positive axons of tamoxifen-
treated SLICK-A Cre; NRG-1fl/fl mice had regenerated a farther
distance through the tibial nerve, this was still significantly re-
duced compared with vehicle-treated animals (tamoxifen vs vehicle
Figure 4. Axon-derived NRG1 is required for remyelination after nerve injury in the adult. A, At 8 weeks after sciatic nerve crush, control (vehicle-treated SLICK-A Cre; NRG-1fl/fl) animals
demonstrated effective remyelination of YFP-expressing axons. B–D, In contrast, YFP-positive axons from conditional NRG1 mutant (tamoxifen-treated SLICK-A Cre; NRG-1fl/fl) mice either had a
significantly thinner myelin sheath (B) or completely failed to elaborate amyelin sheath (C; quantified inD, G-ratio plot; p 0.001, Kolmogorov–Smirnov test). Note in B a neighboring axon that
is YFP negative is normally myelinated. E, Graphic plot displaying numbers of unmyelinated YFP-positive axons (n 4 animals per group). Vh., Vehicle; Tx., tamoxifen. Scale bar, 500 nm.
Figure 5. NRG1-deficient axons could be visualized in the gastrocnemius muscle with no myelin sheath 8 weeks after sciatic
nerve crush. A, In SLICK-A Cre; NRG-1fl/fl animals, regenerated motor axons (YFP, green) at 8 weeks after sciatic nerve crush that
have reinnervated an-bungarotoxin (red)-labeled NMJ can be visualized. MBP staining (blue) colocalizes with YFP staining. B,
NMJ from tamoxifen-treated SLICK-A Cre; NRG-1fl/fl animal (i.e., conditional NRG1mutant); MBP staining is frequently absent over
long lengths from YFP-labeled axons, despite neighboring non-YFP axons staining for MBP. Scale bar, 10m.
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treatment of SLICK-A Cre; NRG-1fl/fl; p 
0.05, two-way ANOVA). At 8 weeks after
crush, the axons had fully regenerated
through the tibial nerve, and no significant
difference between the groups was observ-
able (Fig. 6).
NRG1 ablation results in excess
terminal sprouting at the
neuromuscular junction after
peripheral nerve injury in adult animals
We examined the consequences of NRG1
ablation on the NMJ. In the gastrocne-
mius muscle of SLICK-A mice, 30% of
NMJs are innervated by YFP-positivemo-
toneurons. In SLICK-A Cre; NRG-1fl/fl
mice 12 weeks after tamoxifen adminis-
tration, the structure of the NMJ was nor-
mal (Fig. 7A). The reinnervation of
gastrocnemius NMJs was then assessed at
10 d, 14 d, and 8 weeks after sciatic nerve
crush. At 10 d, the level of NMJ reinner-
vation was low in both groups and did not
significantly differ between them (1.4 0.5
vs 2.5 0.6% of gastrocnemius NMJs were
innervated byYFP-positive axons at 10 d af-
ter crush in the tamoxifen vs vehicle treat-
ment groups of SLICK-A Cre; NRG-1fl/fl
animals; p 0.2). At 14 d after crush, NMJ
reinnervation was more established; the
proportion of NMJs that were reinnervated
by YFP-positive axons was not significantly
different comparing tamoxifen-treatedwith
vehicle-treated SLICK-A Cre; NRG-1fl/fl an-
imals (20.5 3.2 vs 18.2 3.2%of gastroc-
nemius NMJs, respectively). However, at
this time, a greaterproportionof theNRG1-
deficient axons demonstrated partial rather
than full innervation (the proportion of
NMJs that were partially innervated by
YFP-positive axons was 10.8  1.25 vs 6.8  1.49% tamoxifen-
treated vs vehicle-treated SLICK-A Cre; NRG-1fl/fl; p  0.05). At 8
weeks after crush, the number of NMJs innervated by YFP-positive
axons had returned to the preinjury level in all groups andwere fully
innervated (30.8 5.5 vs 22.8 3.4% tamoxifen-treated vs vehicle-
treatedSLICK-ACre;NRG-1fl/fl; no significantdifference).Although
in the tamoxifen-treated SLICK-A Cre; NRG-1fl/fl group the NMJ
was fully reinnervated at this time point, there was a much higher
rate of terminal sprouting (Fig. 7D,E). These sprouts were associ-
ated with the processes of terminal Schwann cells as revealed by
immunostaining with S100 antibodies.
Discussion
In this study, we used SLICK mice to ablate NRG1 conditionally
in a subset of adult sensory and motoneurons. We have found
that axons lacking NRG1 were able to maintain a myelin sheath
but were severely impaired in remyelination after nerve injury.
Such axons also showed a slower rate of regeneration, and, al-
though they reinnervated their targets, the neuromuscular junc-
tion demonstrated excessive terminal sprouting.
The expression of the SLICK transgene in a subpopulation of
sensory and motor neurons enabled us to probe the role of jux-
tacrine NRG1 signaling in the maintenance of the myelin sheath.
There is evidence that a transcriptional program maintains the
Schwann cell myelinating phenotype in adulthood. Krox20 is a
key transcriptional regulator of myelination during development
(Topilko et al., 1994), and conditional ablation ofKrox20 in adult
Schwann cells results in rapid myelin breakdown accompanied
by the expression of genes such as Sox2 associated with Schwann
cell dedifferentiation (Le et al., 2005; Decker et al., 2006). The fact
that in vitro axon contact promotes Krox20 expression by
Schwann cells (Murphy et al., 1996) and that loss of axonal con-
tact in vivo results in downregulation of Krox20 [and other my-
elin related genes (Zorick et al., 1996)] might suggest that NRG1
is required for continued Krox20 expression and myelin mainte-
nance.We did not find, however, that juxtacrine NRG1 signaling
was required for myelin maintenance. At 22 weeks after tamox-
ifen administration to SLICK-A Cre; NRG-1fl/fl animals, YFP
axon and myelin morphology remained normal. The exact half-
life of the NRG1 protein is unknown, so the actual period of
NRG1 deficiency may be less than the full 22 weeks. Because we
only ablated NRG1 in a subset of axons, neighboring axons, or
even Schwann cells (Rosenbaum et al., 1997) might release Ig-
containing NRG1 isoforms, which could signal in a paracrine
manner and theoretically compensate for the absent juxtacrine
NRG1 signaling in tamoxifen-treated SLICK-A Cre; NRG-1fl/fl
Figure6. NRG1-deficient axons regenerate at a slower rate.A,B, YFP-positive axons (seearrows)within the full thickness of the
tibial nerve can be visualized using confocal microscopy 10 d after sciatic nerve crush in vehicle-treated (A) and tamoxifen-treated
(B) SLICK-ACre; NRG-1fl/flanimals. Note the smaller number of regeneratingaxons in the conditionalNRG1mutant (i.e., tamoxifen-
treated SLICK-A Cre; NRG-1fl/fl). This is quantified in C–E, expressed as a percentage of axons relative to the contralateral uncrushed
side versus distance from crush site. There is a significant difference between the tamoxifen- and vehicle-treated group at both 10
(C) and 14 (D) days after crush (n 7 per group; *p 0.05, **p 0.005, two-way ANOVA post hoc Tukey’s test). E, At 2months
after crush, axonshadeffectively regenerated through the tibial nerve in bothgroups,withno significant differencebetween them
(n 5 per group). Vh., Vehicle; Tx., tamoxifen. Scale bars, 500m.
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animals. Conditional ablation of ErbB2, the receptor that partic-
ipates in NRG1 signal transduction, in Schwann cells of mature
mice does not result in any change in myelinated fiber morphol-
ogy up to 2 months after tamoxifen administration, supporting
the notion that ongoingNRG1–ErbB signaling is not required for
myelin maintenance (Atanasoski et al., 2006).
Traumatic nerve injury results in a sequence of cellular
changes termed Wallerian degeneration: distal axonal segments
degenerate, myelin breaks down, Schwann cells dedifferentiate/
proliferate, and macrophages phagocytose debris (Chen et al.,
2007). Subsequently, axons regenerate into bands of Bungner
(Schwann cells within tubes of basal lamina), Schwann cells differ-
entiate into amyelinating phenotype (Zorick et al., 1996), axons are
remyelinated, and saltatory conduction is reestablished. Of note, re-
myelinated fibershave a thinnermyelin sheath (Schro¨der, 1972) and
shorter internodal distance (Minwegen and Friede, 1985).
Given its key developmental role, we investigated whether
NRG1 provides an axoglial signal promoting remyelination. It
has been shown previously that nerve
injury results in increased expression of
the ErbB2 and ErbB3 receptors within
Schwann cells of the distal nerve (Cohen
et al., 1992; Carroll et al., 1997; Kwon et
al., 1997). Changes in the expression of
Neuregulin-1 isoforms after injury are
complex. Expression of the type III iso-
form, the isoform responsible for myeli-
nation, in sensory and motoneurons
decreases initially and then returns to nor-
mal levels as axons reinnervate peripheral
targets (Bermingham-McDonogh et al.,
1997). In contrast, the expression of iso-
forms containing Ig-like domains in-
creases at the site of injury (Carroll et al.,
1997).
We observed at 2 months after sciatic
nerve crush that axons lacking NRG1 had
significantly thinner myelin sheaths, and
40% had completely failed to elaborate a
myelin sheath despite being ensheathed
by Schwann cells.While visualizingmotor
axons, it was clear that long lengths of
NRG1-deficient axons were amyelinated.
The type III isoform of NRG1 requires
proteolytic cleavage by BACE1 for full
activity, and reduced remyelination of ax-
ons has also been observed in BACE/
mice (Hu et al., 2008). Not all aspects of
the Schwann cell response to axon injury
are, however, dependent on NRG1–ErbB
signaling. In a previous study in which the
ErbB2 receptor was conditionally ablated
in adult Schwann cells, no effect on
Schwann cell proliferation distal to a site of
nerve transaction was noted (Atanasoski et
al., 2006). Given the small proportions of
axons in which we ablated NRG1 in this
study, we did not analyze Schwann cell pro-
liferation here.
It is well established that the response
of Schwann cells after nerve injury pro-
motes axon regeneration (Chen et al.,
2007). This is likely to be mediated
through multiple mechanisms, including the expression of neu-
rotrophic factors, extracellular matrix components, and removal
ofmyelin components that are inhibitory to axonal outgrowth. In
axons lacking NRG1, axonal regeneration was slowed at 10 and
14 d after sciatic nerve crush, but at 8 weeks there was no differ-
ence from control. Altered interactions with Schwann cells could
have a role in the slowed regeneration of NRG1-deficient axons,
for instance, a reduction in the synthesis of factors that promote
axonal outgrowth. Addition of soluble NRG1 to the culture me-
dia promotes axon outgrowth from cultured superior cervical
ganglion neurons; this effect is indirect and occurs via the release
of growth-promoting agents from Schwann cells in response to
NRG1 (Mahanthappa et al., 1996). Impairedmyelination per se is
unlikely to cause the slowed axon regeneration. In the control
animals, myelination had not commenced in themajority of YFP
axons in the sciatic nerve at 10 days after crush, a timewhen there
was a clear difference in regeneration of these axons into the tibial
nerve (our unpublished observations). NRG1 might promote
Figure7. NRG1 ablation results in excess terminal sprouting at the neuromuscular junction after peripheral nerve injury.A, The
neuromuscular junction 12 weeks after tamoxifen administration to SLICK-A Cre; NRG-1fl/fl animals (conditional NRG1 mutant)
demonstrated normal apposition and morphology of presynaptic and postsynaptic elements (YFP, green; S100, blue;
-bungarotoxin, red, respectively). B, C, At 8 weeks after sciatic nerve crush; C, NMJs of conditional NRG1 mutant animals were
reinnervatedbut hadamuchhigher degree of terminal sprouting comparedwith control (B). These axonal sprouts clearly followed
the processes of terminal Schwann cells immunolabeled by S-100 (blue). D, There was a significant increase in the proportion of
NMJs with sprouts (**p 0.005, one-way ANOVA post hoc Tukey’s test). E, When terminal sprout length is plotted as cumulative
sum distributions, sciatic crush results in a small but significant increase in sprout length in vehicle-treated animals ( p 0.005,
Kolmogorov–Smirnov test), but sprout length is significantly greater in tamoxifen-treated animals ( p 0001, Kolmogorov–
Smirnov test). n 3 animals per group. Vh., Vehicle; Tx., tamoxifen. Scale bars, 10m.
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axon outgrowth in a cell-autonomous manner by “back signal-
ing” of transmembrane NRG1 isoforms. ErbB binding to NRG1
has been shown in certainmodel systems to result in -secretase-
dependent cleavage, releasing the intracellular domain that is tar-
geted to the nucleus in which it modulates gene transcription
(Bao et al., 2003). It was recently reported that axon outgrowth in
developing cortical neurons can be modulated by expression of
the type III isoform of NRG1, which appeared to be independent
of back signaling and was mediated by an as yet unidentified
signaling system (Chen et al., 2010).
Recent analysis ofmutantmice suggest that NRG1 signaling is
dispensable for NMJ formation (Escher et al., 2005; Jaworski and
Burden, 2006). We did not observe changes in NMJ structure
after NRG1 ablation in adult motoneurons. At 2 weeks after sci-
atic nerve crush, there was no difference in the total number of
NMJs reinnervated by axons lacking NRG1, although a greater
number were partially rather than fully reinnervated. The mild
phenotype in neuromuscular reinnervation compared with the
clear reduction in long-range axon regeneration may correlate
with a greater capacity of NRG1-deficient axons to sprout locally
once they reach their targets. At 8 weeks after injury, theNMJwas
fully reinnervated in all groups, but amuch higher level of termi-
nal sprouting was noted in axons lacking NRG1. Terminal
sprouting is a phenomenon that is triggered by denervation or
inhibition of synaptic transmission (e.g., from botulinum toxin)
at the NMJ (Kang et al., 2003). We found, as others have de-
scribed previously, that such terminal sprouts follow terminal
Schwann cell processes (Son and Thompson, 1995). These spe-
cialized nonmyelinating Schwann cells cap the NMJ and have
been shown to respond toNRG1–ErbB signaling. Treatmentwith
exogenous NRG1 rescues terminal Schwann cells from apoptosis
after neonatal axotomy (Trachtenberg and Thompson, 1996),
and expression of constitutively active ErbB2 in Schwann cells
results in proliferation and process extension from these cells
(Hayworth et al., 2006). Our findings suggest that axonally de-
rived NRG1 is clearly dispensable for terminal Schwann cell pro-
cess extension. The excess terminal sprouting that we observed
may not be a direct consequence of the absence of NRG1 at the
NMJ itself but instead secondary to the grossly impaired remyeli-
nation of themotor axons. IncreasedNMJ terminal sprouting has
been described previously in a mutant mouse model of a demy-
elinating neuropathy, EGR2 I268N, as a consequence of conduc-
tion block (Baloh et al., 2009).
In conclusion, during adulthood, NRG1 has a key role in me-
diating the signaling between axons and Schwann cells required
for effective nerve repair. Our data indicate that therapeutics
based on the inhibition of ErbB signaling in oncology (Lurje and
Lenz, 2009) and BACE1 in Alzheimer’s disease (Vassar et al.,
2009) will not impair normal nerves but will significantly inter-
fere with the regenerative response to nerve injury.
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